Abstract
Background
Increasing evidence has suggested that RhoE plays an important role in carcinogenesis and progression. However, the correlation between RhoE expression and clinical outcome in lung cancer has not been investigated.
Methods
RhoE expression was detected by immunohistochemistry on tissue microarray containing samples from 115 patients with non–small cell lung cancer with a median follow-up of 54 months.
Results
RhoE was overexpressed in the cytoplasm of lung cancer cells compared with undetectable expression of RhoE in the adjacent nontumoral cells. Patients with RhoE-negative tumors had substantially longer cancer-related survival than did patients with RhoE-positive tumors. Multivariate analysis showed that RhoE overexpression was an independent marker for cancer-related survival in the entire population after adjusting for other prognostic factors.
Conclusions
RhoE expression may serve as an unfavorable prognostic factor in patients with non–small cell lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005 cancer. Cancer Epidemiol Biomarkers Prev 2005;14:243–50
Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer 2004;90:2157–66
Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 1999;59:2004–10
Pille JY, Denoyelle C, Varet J, et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005;11:267–74
Liu N, Bi F, Pan YL, et al. The expression and possible function of RhoA in human gastric cancer cell lines. Zhonghua Zhong Liu Za Zhi 2004;26:26–9
Kamai T, Yamanishi T, Shirataki H, et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 2004;10:4799–805
Kamai T, Kawakami S, Koga F, et al. RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int 2003;91:234–8
Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83:861–70
Yao H, Dashner EJ, van Golen CM, et al. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 2006;25:2285–96
Shikada Y, Yoshino I, Okamoto T, et al. Higher expression of RhoC is related to invasiveness in non–small cell lung carcinoma. Clin Cancer Res 2003;9:5282–6
Kleer CG, van Golen KL, Zhang Y, et al. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002;160:579–84
Kleer CG, Griffith KA, Sabel MS, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 2005;93:101–10
Ikoma T, Takahashi T, Nagano S, et al. A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin Cancer Res 2004;10:1192–200
Bellovin DI, Simpson KJ, Danilov T, et al. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006;25:6959–67
Han ZQ, Zhang AL, Wu MF, et al. Correlation of expression of RhoA, RhoC and their effector ROCK-1 with malignant phenotype of ovarian cancer cells in vitro. Zhonghua Zhong Liu Za Zhi 2004;26:385–8
Adnane J, Muro-Cacho C, Mathews L, et al. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res 2002;8:2225–32
Mazieres J, Antonia T, Daste G, et al. Loss of RhoB expression in human lung cancer progression. Clin Cancer Res 2004;10:2742–50
Foster R, Hu KQ, Lu Y, et al. Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation. Mol Cell Biol 1996;16:2689–99
Guasch RM, Scambler P, Jones GE, et al. RhoE regulates actin cytoskeleton organization and cell migration. Mol Cell Biol 1998;18:4761–71
Zhang CY, Hang J, Zhou F, et al. Overexpression of RhoE in non–small cell lung cancer (NSCLC) is associated with smoking and correlates with DNA copy number changes. Cancer Biol Ther 2007;6:335–42
Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657–62
Trojan L, Schaaf A, Steidler A, et al. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res 2005;25:183–91
Villalonga P, Guasch RM, Riento K, et al. RhoE inhibits cell cycle progression and Ras-induced transformation. Mol Cell Biol 2004;24:7829–40
Bektic J, Pfeil K, Berger AP, et al. Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate 2005;64:1–9
Lokeshwar VB, Cerwinka WH, Isoyama T, et al. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 2005;65:7782–9
Acknowledgments
Supported by grant 2002BA711A06 from the National High Technology Research and Development Program of China (863 Program). We thank Kezhi Zhang and Xinhua Mu for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, C., Zhou, F., Li, N. et al. Overexpression of RhoE Has a Prognostic Value in Non–Small Cell Lung Cancer. Ann Surg Oncol 14, 2628–2635 (2007). https://doi.org/10.1245/s10434-007-9457-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-007-9457-x